Phyllis S Scher, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 300 Bay Shore Rd, North Babylon, NY 11703 Phone: 631-586-2700 Fax: 631-586-3524 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.
Generic public health messages, such as 'eat 5 fruit and vegetables a day', are more effective at shifting dietary habits than very specific advice and guidance tailored according to individual needs, say researchers.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
Injections received in the months prior to total knee (TKR) or total hip replacement (THR) surgery may increase the risk for infection and related complications, according to two studies-among the largest conducted on this topic-presented at the 2016 Annual Meeting of the American Academy of Orthopaedic Surgeons.
Researchers have made a giant leap towards the goal of 'bio-printing' transplantable tissues and organs for people affected by major diseases and trauma injuries, a new study reports.
› Verified 7 days ago